4D Molecular Therapeutics, Inc. FDMT
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
What this company does
Written from the business description in 4D Molecular Therapeutics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 18 March 2026. Every sentence was checked against that document before publication.
Growth
Revenue compounded at +44.3% a year over the five years to FY2025.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
Each USD of equity lost 28 cents this year.
The 7-year record
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue $B | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 |
| EBITDA $B | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ◌ |
| Net income $B | −0.1 | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 |
| Free cash flow $B | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 |
| EPS, diluted $ | −2.42 | −2.98 | −2.58 | −3.32 | −2.57 | −8.82 | −9.59 |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — |
| ROE % | −27.6 | −39.3 | −37.4 | −39.1 | −24.8 | — | — |
| Shares out B | 0.06 | 0.05 | 0.04 | 0.03 | 0.03 | 0.03 | 0.01 |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Company facts, as filed
Reconciled in 7 of the 7 fiscal years we could check. 24 checks were skipped: the balance sheet is not tagged before 2019. 12 checks were skipped: EPS is not tagged before 2019.